Results 141 to 150 of about 3,657 (192)

New drugs for the management of tuberculosis. [PDF]

Curr Opin Infect Dis
Cross GB.
europepmc   +1 more source

Dietary Intake Analyses for the Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis (PandrTB) Pharmacokinetic Sub-Study of the endTB and endTB-Q Clinical Trials

Hans L, Swart R, Velásquez GE, Mitnick CD, Guglielmetti L, Velarde FG, Arshad MS, Magzumova A, Stambekova A, Mohale S, Nguyen HT, Varaine F, McIlleron H.   +12 more
europepmc   +1 more source

Bedaquiline and delamanid in tuberculosis

Expert Opinion on Pharmacotherapy, 2015
In recent years, a pressing need to develop new, effective and safe drugs against tuberculosis (TB) has continued. Poor adherence to a long therapeutic regimen against TB, intermittent drug use, errors in medical prescriptions, low quality of old TB drugs and ineffective TB control have led to the emergence of resistant TB.Two new drugs have gained ...
Francesco Blasi, Susanna Esposito, Sonia Bianchini   +2 more
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis

Tuberculosis, 2018
Delamanid, a bicyclic nitroimidazooxazole, is effective against M. tuberculosis. Previous studies have shown that resistance to a bicyclic nitroimidazooxazine, PA-824, is caused by mutations in an F420-dependent bio-activation pathway. We investigated whether the same mechanisms are responsible for resistance to delamanid.
Yongge Liu
exaly   +3 more sources

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis [PDF]

Antimicrobial Agents and Chemotherapy, 2022
A population pharmacokinetic analysis of delamanid and its major metabolite DM-6705 was conducted to characterize the pharmacokinetics of delamanid and DM-6705 in pediatric participants with multidrug-resistant tuberculosis (MDR-TB).
Elin Svensson, Mats Karlsson
exaly   +2 more sources

Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment [PDF]

Clinical Infectious Diseases, 2019
Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired
Katharina Kranzer, Stefan Niemann, Matthias Merker   +2 more
exaly   +2 more sources

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

International Journal of Tuberculosis and Lung Disease, 2011
BACKGROUND: Delamanid (OPC-67683) is a novel mycolic acid biosynthesis inhibitor active against Mycobacterium tuberculosis at a low minimum inhibitory concentration. METHODS: Forty-eight patients with smear-positive tuberculosis (63% male; 54.7 ± 9.9 kg;
A H Diacon, P R Donald, A Venter
exaly   +2 more sources

Delamanid: First Global Approval

Drugs, 2014
Delamanid, a nitro-dihydro-imidazooxazole derivative, has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis (MDR-TB). Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimised background therapy.
Nicola J, Ryan, Jin Han, Lo
openaire   +2 more sources